Page 1

West By your side for a healthier world " Exhibit 99.1 West Announces Second - Quarter 2021 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton , PA , July 29 , 2021 - West Pharmaceutical Services , Inc. ( NYSE : WST ) today announced its financial results for the second - quarter 2021 and updated full - year 2021 financial guidance . Second - Quarter 2021 Summary ( comparisons to prior - year period ) • Net sales of $ 723.6 million grew 37.3 % ; organic sales growth was 30.6 % . • • Reported - diluted EPS of $ 2.47 increased 104 % . Adjusted - diluted EPS of $ 2.46 increased 97 % . Company is raising full - year 2021 net sales guidance to a new range of $ 2.760 billion to $ 2.785 billion , compared to a prior range of $ 2.630 billion to $ 2.655 billion . Company is raising full - year 2021 adjusted - diluted EPS guidance to a new range of $ 8.05 to $ 8.20 , compared to a prior range of $ 6.95 to $ 7.10 . " Adjusted - diluted EPS " and " organic sales growth " are Non - U.S . GAAP measurements . See discussion under the heading " Non - U.S . GAAP Financial Measures " in this release . " Our strong second quarter performance was driven by continued momentum in organic sales growth in both our base business as well as increased demand for our products associated with COVID - 19 vaccines , " said Eric M. Green , President and Chief Executive Officer . " Guided by our mission , our dedicated team members remain focused on meeting the increased demand for our high - value product ( HVP ) components . Our market - led strategy coupled with our scientific leadership and regulatory insights in primary packaging and delivery of injectable drugs have resonated with our customers , resulting in a high participation rate on newly approved molecular entities , especially large molecule therapies . Over the past year and half , we have accelerated capital spending and expanded global HVP manufacturing capacity . Based on growing future demand from our customers , we are announcing another tranche of capital spending to expand HVP capacity that we expect will be ready for production in 2022. Given the strong first half of the year , we are raising our full - year financial guidance . " Proprietary Products Segment Net sales grew by 47.0 % to $ 587.3 million . Organic sales growth was 39.3 % , with currency translation increasing sales growth by 770 basis points . HVP sales represented over 70 % of segment sales and generated double - digit organic sales growth , led by customer demand for Westar® , NovaPure® , FluroTec® , DaikyoⓇ and Envision® components . The Biologics and Pharma market units had strong double - digit organic sales growth , and the Generics market unit had low - single digit organic sales growth .